7o30 - Revision history

OCA at 12:43, 1 February 2024

2024-02-01T12:43:59Z

←Older revision		Revision as of 12:43, 1 February 2024
Line 1:		Line 1:

-	====	+	==Crystal structure of the anti-PAS Fab 1.1 in complex with its epitope peptide==
-	<StructureSection load='7o30' size='340' side='right'caption='[[7o30]]' scene=''>	+	<StructureSection load='7o30' size='340' side='right'caption='[[7o30]], [[Resolution\|resolution]] 2.65Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7o30]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7O30 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7O30 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7o30 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7o30 OCA], [https://pdbe.org/7o30 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7o30 RCSB], [https://www.ebi.ac.uk/pdbsum/7o30 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7o30 ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.65Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7o30 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7o30 OCA], [https://pdbe.org/7o30 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7o30 RCSB], [https://www.ebi.ac.uk/pdbsum/7o30 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7o30 ProSAT]</span></td></tr>
	</table>		</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Pro/Ala-rich sequences (PAS) are polypeptides that were developed as a biological alternative to poly-ethylene glycol (PEG) to generate biopharmaceuticals with extended plasma half-life. Like PEG, PAS polypeptides are conformationally disordered and show high solubility in water. Devoid of any charged or prominent hydrophobic side chains, these biosynthetic polymers represent an extreme case of intrinsically disordered proteins. Despite lack of immunogenicity of PAS tags in numerous animal studies we now succeeded in generating monoclonal antibodies (MAbs) against three different PAS versions. To this end, mice were immunized with a PAS#1, P/A#1 or APSA 40mer peptide conjugated to keyhole limpet hemocyanin as highly immunogenic carrier protein. In each case, one MAb with high binding activity and specificity towards a particular PAS motif was obtained. The apparent affinity was strongly dependent on the avidity effect and most pronounced for the bivalent MAb when interacting with a long PAS repeat. X-ray structural analysis of four representative anti-PAS Fab fragments in complex with their cognate PAS epitope peptides revealed interactions dominated by hydrogen bond networks involving the peptide backbone as well as multiple Van der Waals contacts arising from intimate shape complementarity. Surprisingly, Ala, the L-amino acid with the smallest side chain, emerged as a crucial feature for epitope recognition, contributing specific contacts at the center of the paratope in several anti-PAS complexes. Apart from these insights into how antibodies can recognize feature-less peptides without secondary structure, the MAbs characterized in this study offer valuable reagents for the preclinical and clinical development of PASylated biologics.
		+
		+	Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope.,Schilz J, Binder U, Friedrich L, Gebauer M, Lutz C, Schlapschy M, Schiefner A, Skerra A J Mol Biol. 2021 Sep 3;433(18):167113. doi: 10.1016/j.jmb.2021.167113. Epub 2021 , Jun 20. PMID:34161780<ref>PMID:34161780</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7o30" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Z-disk~~]]	+	[[Category: Mus musculus]]
		+	[[Category: Synthetic construct]]
		+	[[Category: Schiefner A]]
		+	[[Category: Schilz J]]
		+	[[Category: Skerra A]]

OCA at 09:59, 7 July 2021

2021-07-07T09:59:12Z

←Older revision		Revision as of 09:59, 7 July 2021
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 7o30 ~~is ON HOLD until Paper Publication~~	+	====
-		+	<StructureSection load='7o30' size='340' side='right'caption='[[7o30]]' scene=''>
-	~~Authors~~: ~~Schilz, J~~.~~, Schiefner, A~~.~~, Skerra, A~~.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description: Crystal structure of the anti~~-~~PAS Fab 1~~.~~1 in complex with its epitope peptide~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7o30 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7o30 OCA], [https://pdbe.org/7o30 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7o30 RCSB], [https://www.ebi.ac.uk/pdbsum/7o30 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7o30 ProSAT]</span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	</table>
-	[[~~Category~~: ~~Schilz~~, J]]	+	__TOC__
-	[[Category: ~~Skerra, A~~]]	+	</StructureSection>
-	[[Category: ~~Schiefner, A~~]]	+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA at 08:18, 12 May 2021

2021-05-12T08:18:25Z

←Older revision		Revision as of 08:18, 12 May 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7o30 is ON HOLD	+	The entry 7o30 is ON HOLD until Paper Publication

	Authors: Schilz, J., Schiefner, A., Skerra, A.		Authors: Schilz, J., Schiefner, A., Skerra, A.

OCA: Protected "7o30" [edit=sysop:move=sysop]

2021-04-07T04:58:03Z

Protected "7o30" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:58, 7 April 2021

OCA: New page: '''Unreleased structure''' The entry 7o30 is ON HOLD Authors: Schilz, J., Schiefner, A., Skerra, A. Description: Crystal structure of the anti-PAS Fab 1.1 in complex with its epitope p...

2021-04-07T04:58:01Z

New page: '''Unreleased structure''' The entry 7o30 is ON HOLD Authors: Schilz, J., Schiefner, A., Skerra, A. Description: Crystal structure of the anti-PAS Fab 1.1 in complex with its epitope p...

New page

'''Unreleased structure'''

The entry 7o30 is ON HOLD

Authors: Schilz, J., Schiefner, A., Skerra, A.

Description: Crystal structure of the anti-PAS Fab 1.1 in complex with its epitope peptide
[[Category: Unreleased Structures]]
[[Category: Schilz, J]]
[[Category: Skerra, A]]
[[Category: Schiefner, A]]